|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets | ||||||||||||||||||||
| Cash and cash equivalents ($320 and $328 related to VIEs) | ||||||||||||||||||||
| Marketable securities ($26 and $39 related to VIEs) | ||||||||||||||||||||
| Accounts receivable, net ($134 and $142 related to VIEs) | ||||||||||||||||||||
| Contract assets ($55 and $17 related to VIEs) | ||||||||||||||||||||
| Investment in NuScale | ||||||||||||||||||||
| Other current assets ($17 and $26 related to VIEs) | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Noncurrent assets | ||||||||||||||||||||
| Marketable securities, noncurrent | ||||||||||||||||||||
| PP&E, net ($40 and $41 related to VIEs) | ||||||||||||||||||||
| Investments | ||||||||||||||||||||
| Deferred taxes | ||||||||||||||||||||
| Deferred compensation trusts | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other assets ($7 and $17 related to VIEs) | ||||||||||||||||||||
| Total noncurrent assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND EQUITY | ||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||
| Accounts payable ($142 and $205 related to VIEs) | ||||||||||||||||||||
| Short-term debt and current portion of long-term debt | ||||||||||||||||||||
| Contract liabilities ($163 and $254 related to VIEs) | ||||||||||||||||||||
| Accrued salaries, wages and benefits ($11 and $9 related to VIEs in both periods) | ||||||||||||||||||||
| Other accrued liabilities ($24 and $31 related to VIEs) | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term debt | ||||||||||||||||||||
| Deferred taxes | ||||||||||||||||||||
| Other noncurrent liabilities ($4 and $3 related to VIEs) | ||||||||||||||||||||
| Equity | ||||||||||||||||||||
| Shareholders’ equity | ||||||||||||||||||||
| Preferred stock — authorized 20,000,000 shares ($0.01 par value); issued and outstanding — 600,000 shares in 2022 | ||||||||||||||||||||
| Common stock — authorized 375,000,000 shares ($0.01 par value); issued and outstanding — 135,564,463 and 152,047,739 shares in 2026 and 2025, respectively | ||||||||||||||||||||
| APIC | ||||||||||||||||||||
| AOCI | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| NCI | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities and equity | ||||||||||||||||||||
Loading...
